Welcome to our dedicated page for China Jo-Jo Drugstores SEC filings (Ticker: CJJD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Investors following China Jo-Jo Drugstores Inc. know that a single quarter can involve three revenue models—brick-and-mortar pharmacies, TCM-focused e-commerce storefronts and a growing wholesale platform. Pulling the right numbers from segment footnotes, deciphering government reimbursement disclosures and tracking supply-chain updates can be time-consuming. Our AI-powered summaries turn pharmaceutical jargon into clear insights and surface the metrics that matter. Consider this your source for China Jo-Jo Drugstores SEC filings explained simply.
Whether you are skimming today’s 8-K for sudden partnerships or diving into the annual report, every CJJD document filed with EDGAR drops here in real time. Popular questions are answered inside the tabs below:
- China Jo-Jo Drugstores insider trading Form 4 transactions—see who bought or sold within minutes.
- China Jo-Jo Drugstores quarterly earnings report 10-Q filing with segment breakouts.
- China Jo-Jo Drugstores 8-K material events explained so you know when partnerships shift.
- China Jo-Jo Drugstores annual report 10-K simplified for retail and institutional readers.
- Understanding China Jo-Jo Drugstores SEC documents with AI: plain-language highlights in one click.
- China Jo-Jo Drugstores proxy statement executive compensation details, boiled down to key tables.
Set custom alerts for China Jo-Jo Drugstores Form 4 insider transactions real-time, follow China Jo-Jo Drugstores earnings report filing analysis and track China Jo-Jo Drugstores executive stock transactions Form 4 before market open. Our AI extracts cash-flow drivers for each business channel, compares them across periods and flags anomalies, letting you move from data to decision without wading through PDFs.
Ridgetech, Inc. (Nasdaq: RDGT) – FY 2025 Form 20-F key points
- Completed Feb-28-25 restructuring: purchased Ridgeline International (online wholesale platform) and divested all retail/VIE assets; post-deal structure is Cayman holdco ▶ HK Renovation ▶ PRC subsidiaries with no VIE exposure.
- 5.86 m ordinary shares outstanding; auditor YCM CPA Inc. is PCAOB-inspected, limiting HFCAA delisting risk.
- Wholesale-only focus: FY25 revenue US$120.0 m (offline $118.9 m, online $1.1 m) -3.2 % YoY after exit from low-margin accounts.
- Customer concentration intense: Jiuzhou Pharmacy & one other account supply 86 % of sales; a 3-yr supply contract with Jiuzhou can be terminated on 1-month notice. Divested entities owe RDGT $13.6 m A/R.
- Planned equity, not loan, funding of PRC ops; historical capital transferred $27.5 m (investments) and $8.7 m (loans).
- Regulatory landscape remains fluid: potential CSRC, CAC and data-security reviews, cash-transfer controls, possible new restrictions on foreign listings.
- Risk factors emphasize customer concentration, receivable collection, counterfeit products, dependence on third-party e-commerce platforms, and need for multiple PRC permits.
FAQ
What is the current stock price of China Jo-Jo Drugstores (CJJD)?
What is the market cap of China Jo-Jo Drugstores (CJJD)?
What are the main business segments of China Jo-Jo Drugstores Inc.?
How does China Jo-Jo Drugstores differentiate itself in the market?
What is the significance of the company's shift to a wholesale-focused model?
What challenges does China Jo-Jo Drugstores face?
What opportunities exist for China Jo-Jo Drugstores in the healthcare industry?
What products does China Jo-Jo Drugstores offer in its retail stores?
What e-commerce platforms does the company use for its online pharmacy segment?
How does the wholesale segment contribute to the company's growth?
